DEVELOP LIVE ATTENUATED CYTOMEGALOVIRUS VACCINES

开发巨细胞病毒减毒活疫苗

• 批准号: 3594783
• 负责人: RICHARD D MACDONALD
• 金额: $ 4.99万
• 依托单位: SYNTRO CORPORATION
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-08-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3594783
• 关键词: Betaherpesvirinae; Herpesviridae disease; Herpesviridae vaccine; genetic manipulation; virus genetics

Human Cytomegalovirus (HCMV) is a significant human pathogen. While HCMV infection does not produce disease in the majority of cases, major problems may develop from congenital infections or in immunocompromised individuals. It is estimated that the cost of vaccine preventable HCMV disease is greater than 800 million dollars annually. Syntro Corporation, using recombinant DNA technology, has developed proprietary attenuated herpes viruses for the animal health industry which in animal trials do not produce detectable stress or pathology, yet induce an immune response which approaches that of an infection by wild-type virus. This technology can now be applied to the attenuation of HCMV in order to produce a safe and effective live viral vaccine candidate. Phase 1 studies will result in the development of an efficient transfection system for HCMV including the production of genomic and purified subgenomic fragments of HCMV DNA. After the appropriate deletions and insertions of marker antigens into selected fragments, Syntro will be positioned to construct a recombinant HCMV with potential as an attenuated vaccine in a Phase 2 study. The commercial production of safe and effective HCMV vaccine will be of great benefit in reducing the disease symptoms of HCMV infection.

人巨细胞病毒（HCMV）是人类重要的病原体。 尽管HCMV 在大多数情况下，感染不会产生疾病， 可能由先天性感染或免疫功能低下 个体 据估计，疫苗可预防的HCMV的成本 每年花费超过8亿美元。 Syntro公司利用重组DNA技术， 用于动物保健行业的专利减毒疱疹病毒， 在动物试验中不会产生可检测到的应激或病理， 接近野生型感染的免疫反应 病毒 这项技术现在可以应用于HCMV的减毒， 以生产安全有效的活病毒候选疫苗。 1期研究将导致开发有效的转染 包括产生基因组和纯化的亚基因组 HCMV DNA片段。 在适当删除和插入 标记抗原转化为选定的片段，将Syntro定位为 构建具有减毒疫苗潜力的重组HCMV， II期研究。 安全有效的人巨细胞病毒的商业化生产 疫苗将对减轻HCMV的疾病症状有很大益处 感染